GlassScriptPhysician profile
James C Thigpen
NPI 1841369105
$1,012.68
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $315 · 2021: $257 · 2022: $178.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $160.31 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $100.25 | 2020-2022 | |
| Abbvie INC. | $88.95 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.05 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $64.32 | 2019-2020 | |
| Antares Pharma, INC. | $56.80 | 2019-2021 | |
| Glaxosmithkline, LLC. | $53.37 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $48.25 | 2022 | |
| Endo Pharmaceuticals INC. | $47.76 | 2020 | |
| Amgen INC. | $41.03 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $28.42 | 2020 | |
| Eisai INC. | $28.04 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.86 | 2020 | |
| Abbott Laboratories | $25.11 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $24.48 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $19.52 | 2022 | |
| Mylan Pharmaceuticals INC. | $14.58 | 2021 | |
| Nestle Healthcare Nutrition INC. | $14.49 | 2021 | |
| Amneal Pharmaceuticals LLC | $14.07 | 2021 | |
| Merck Sharp & Dohme LLC | $13.41 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.59 | 2021 | |
| Dexcom, INC. | $12.51 | 2022 | |
| Amarin Pharma, INC. | $11.59 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.56 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $11.29 | 2019 | |
| Pfizer INC. | $11.07 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Thigpen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.